Core Insights - Prelude Therapeutics announced the acceptance of a poster presentation for its oral KAT6A selective degrader (PRT13722) at the AACR Annual Meeting 2026, scheduled for April 17-22 [1] - The company aims to file an IND in mid-2026 and initiate clinical trials in the second half of 2026 for PRT13722, which is expected to improve efficacy and tolerability in treating ER+ breast cancer [2][4] Presentation Details - The poster titled "First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profile" will be presented on April 21, 2026, from 2:00 PM to 5:00 PM [3] - The presentation will be part of the Experimental and Molecular Therapeutics session, located at Poster Section 15, Board Number 20, Poster Number 5793 [3] Product Development - Prelude is developing a highly selective KAT6A oral degrader, which is believed to offer improved efficacy and tolerability compared to non-selective inhibitors [4] - The company has previously presented initial preclinical data supporting the potential of KAT6A as a target for ER+ breast cancer at the AACR Annual Meeting 2025 [5] Educational Session - On April 18, 2026, Prelude's Director of Biology and Translational Research will present a lecture on "Beyond Conventional Payloads: Unlocking New Therapeutic Landscapes with Targeted Protein Degrader-Antibody Conjugates (DACs)" during an educational session [6] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, including KAT6A degraders and JAK2V617F mutant selective inhibitors, targeting areas of high unmet need in cancer treatment [6]

Core Insights - Prelude Therapeutics has received FDA clearance for the Investigational New Drug (IND) application for PRT12396, a mutant-selective JAK2V617F inhibitor, with a Phase 1 study expected to start in Q2 2026 [1][4] - The company is also advancing PRT13722, a highly-selective oral KAT6A degrader, with an IND filing anticipated in mid-2026 and Phase 1 study initiation planned for the second half of 2026 [1][5] - Prelude's current cash runway is projected to last into Q2 2027, with $106 million in cash and equivalents as of December 31, 2025 [1][14] R&D Pipeline Updates - The JAK2V617F mutation is a significant driver in myeloproliferative neoplasms (MPNs), affecting approximately 95% of polycythemia vera patients, 60% of essential thrombocythemia patients, and 55% of myelofibrosis patients [3] - Prelude has developed novel allosteric inhibitors targeting the JAK2 JH2 "deep pocket" where the V617F mutation resides, showing potential to reduce mutant allele burden and improve treatment outcomes for MPN patients [3] - The KAT6A oral degrader program targets ER+ breast cancer, with the potential for improved efficacy and tolerability compared to non-selective inhibitors [5] Financial Performance - For the year ended December 31, 2025, Prelude reported a net loss of $99.5 million, or $1.29 per share, a decrease from a net loss of $127.2 million, or $1.68 per share, in the previous year [17][21] - Research and development expenses decreased to $94.3 million from $118.0 million in the prior year, attributed to reduced stock-based compensation and discontinued clinical trials [15] - General and administrative expenses also decreased to $22.4 million from $28.7 million, primarily due to lower stock-based compensation and employee-related expenses [16] Upcoming Milestones - The Phase 1 study of PRT12396 will be an open-label, multi-center trial focusing on patients with high-risk polycythemia vera and intermediate to high-risk myelofibrosis [4] - Prelude plans to present initial preclinical data for its KAT6A program at upcoming conferences, showcasing its commitment to advancing its R&D pipeline [6][11] - The company will participate in the Citizens Life Sciences Conference on March 10, 2026, where key executives will discuss the company's strategic direction and upcoming milestones [12]

Core Insights - Prelude Therapeutics has received FDA clearance for its Investigational New Drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor, with a Phase 1 study expected to start in Q2 2026 [1][4] - The company is also advancing its KAT6A degrader program, with an IND filing anticipated in mid-2026 and a Phase 1 study initiation planned for the second half of 2026 [1][5] - Prelude's current cash runway is projected to extend into Q2 2027, with $106 million in cash and equivalents as of December 31, 2025 [1][14] R&D Pipeline Updates - The JAK2V617F mutation is prevalent in 95% of polycythemia vera (PV) patients, 60% of essential thrombocythemia (ET) patients, and 55% of myelofibrosis (MF) patients, making it a critical target for treatment [3] - Prelude has developed novel allosteric inhibitors that specifically target V617F+ cells, aiming to reduce mutant allele burden and improve treatment outcomes for patients with myeloproliferative neoplasms (MPNs) [3] - The KAT6A oral degrader program targets ER+ breast cancer, with the potential for improved efficacy and tolerability compared to non-selective inhibitors [5] Financial Performance - For the year ended December 31, 2025, Prelude reported a net loss of $99.5 million, or $1.29 per share, a decrease from a net loss of $127.2 million, or $1.68 per share, in the previous year [17][21] - Research and development expenses decreased to $94.3 million from $118.0 million in the prior year, attributed to reduced stock-based compensation and discontinued clinical trials [15] - General and administrative expenses also saw a decline to $22.4 million from $28.7 million, primarily due to lower stock-based compensation and employee-related expenses [16] Upcoming Milestones - The company is on track to have both PRT12396 and PRT13722 in clinical development in 2026, which may lead to significant data catalysts in 2027 [2] - Prelude will participate in the Citizens Life Sciences Conference on March 10, 2026, where key executives will discuss the company's progress and future plans [12]